Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.2K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.2K
Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

1.8K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
1.8K
Chromatin Modification in iPS Cells01:32

Chromatin Modification in iPS Cells

1.6K
Chromatin modification alters gene expression; therefore, scientists can add histone-modifying enzymes, histone variants, and chromatin remodeling complexes to somatic cells to aid reprogramming into pluripotent stem (iPS) cells.
Compact chromatin makes reprogramming difficult. Enzymes, such as histone demethylases and acetyltransferases, are often added during reprogramming to loosen the chromatin, making the DNA more accessible to transcription factors. Molecules that inhibit histone...
1.6K
Introduction to Nuclear Reprogramming01:14

Introduction to Nuclear Reprogramming

1.9K
Nuclear reprogramming is the process of switching gene expression of one cell type to that of another cell type, usually from a differentiated cell state to an undifferentiated cell state. Differentiation occurs during processes such as development and morphogenesis, tissue regeneration, and malignancy. Cells can also be artificially induced to reprogram their gene expression by techniques such as nuclear transfer, induced pluripotency, and cell fusion. Such techniques have many applications in...
1.9K
Epigenetic Regulation01:37

Epigenetic Regulation

3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia.

Cell·2025
Same author

Discovery and Characterization of VPRBP/DCAF1 Kinase Inhibitor Analogs as Microtubular Destabilizing Agents with Potent Antimyeloma Activity.

Molecular cancer therapeutics·2025
Same author

Experiences of Maryland Primary Care Practices in Addressing Social Needs Through a Novel Value-Based Payment.

Health services research·2025
Same author

Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors.

Nature communications·2025
Same author

Barriers and facilitators to screen for and address social needs in primary care practices in Maryland: a qualitative study.

Frontiers in health services·2024
Same author

SUMO protease FUG1, histone reader AL3 and chromodomain protein LHP1 are integral to repeat expansion-induced gene silencing in Arabidopsis thaliana.

Nature plants·2024

Related Experiment Video

Updated: May 16, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K

Epigenetic reprogramming in multiple myeloma-Challenges and opportunities.

Subhasree Kumar1, Lev M Kats1,2, Emily Gruber1

  • 1Peter MacCallum Cancer Centre and the Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

International Journal of Cancer
|April 2, 2025
PubMed
Summary

Epigenetic alterations drive cancer, offering a plastic adaptation mechanism. Understanding these changes in multiple myeloma is key to developing new treatments targeting the aberrant epigenome.

Keywords:
epigenetic drugsepigeneticsmultiple myeloma

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Related Experiment Videos

Last Updated: May 16, 2025

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
10:04

Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis

Published on: May 1, 2015

13.0K
Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
07:24

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

6.3K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.6K

Area of Science:

  • Oncology
  • Epigenetics
  • Cancer Biology

Background:

  • Cancer development involves genetic mutations and epigenetic reprogramming.
  • Epigenetic changes, unlike genetic mutations, are plastic and allow rapid cellular adaptation.
  • Multiple myeloma exhibits significant genetic and epigenetic heterogeneity, complicating treatment.

Purpose of the Study:

  • To review common epigenetic alterations in multiple myeloma.
  • To explore the interplay between genetic and epigenetic evolution in tumorigenesis.
  • To discuss novel therapeutic strategies targeting the myeloma epigenome.

Main Methods:

  • Literature review of epigenetic alterations in multiple myeloma.
  • Analysis of genetic and non-genetic evolutionary mechanisms in cancer.
  • Discussion of emerging epigenetic reversal strategies.

Main Results:

  • Epigenetic reprogramming is a hallmark of cancer, contributing to malignant properties.
  • Chromatin plasticity facilitates rapid adaptation of cancer cells to environmental changes.
  • Common epigenetic alterations in multiple myeloma are extensively characterized.

Conclusions:

  • Understanding epigenetic alterations is crucial for improving multiple myeloma patient outcomes.
  • Targeting the aberrant epigenome represents a promising therapeutic avenue for myeloma.
  • The interplay of genetic and epigenetic factors drives myeloma progression.